Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 4:14:1303076.
doi: 10.3389/fimmu.2023.1303076. eCollection 2023.

Role of MCP-1 as an inflammatory biomarker in nephropathy

Yanlong Liu  1 , Ke Xu  2 , Yuhua Xiang  3 , Boyan Ma  2 , Hailong Li  3 , Yuan Li  4 , Yue Shi  2 , Shuju Li  3 , Yan Bai  3
Affiliations
Review

Role of MCP-1 as an inflammatory biomarker in nephropathy

Yanlong Liu et al. Front Immunol. .

Abstract

The Monocyte chemoattractant protein-1 (MCP-1), also referred to as chemokine ligand 2 (CCL2), belongs to the extensive chemokine family and serves as a crucial mediator of innate immunity and tissue inflammation. It has a notable impact on inflammatory conditions affecting the kidneys. Upon binding to its receptor, MCP-1 can induce lymphocytes and NK cells' homing, migration, activation, differentiation, and development while promoting monocytes' and macrophages' infiltration, thereby facilitating kidney disease-related inflammation. As a biomarker for kidney disease, MCP-1 has made notable advancements in primary kidney diseases such as crescentic glomerulonephritis, chronic glomerulonephritis, primary glomerulopathy, idiopathic proteinuria glomerulopathy, acute kidney injury; secondary kidney diseases like diabetic nephropathy and lupus nephritis; hereditary kidney diseases including autosomal dominant polycystic kidney disease and sickle cell kidney disease. MCP-1 not only predicts the occurrence, progression, prognosis of the disease but is also closely associated with the severity and stage of nephropathy. When renal tissue is stimulated or experiences significant damage, the expression of MCP-1 increases, demonstrating a direct correlation with the severity of renal injury.

Keywords: MCP-1; hereditary nephropathy; inflammatory markers; primary nephropathy; secondary nephropathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Role of MCP-1 as an inflammatory marker in nephropathy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. He S, Yao L, Li J. Role of MCP-1/CCR2 axis in renal fibrosis: Mechanisms and therapeutic targeting. Med (Baltimore) (2023) 102(42):e35613. doi: 10.1097/md.0000000000035613 - DOI - PMC - PubMed
    1. Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J (2018) 285(16):2944–71. doi: 10.1111/febs.14466 - DOI - PMC - PubMed
    1. Singh S, Anshita D, Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol (2021) 101(Pt B):107598. doi: 10.1016/j.intimp.2021.107598 - DOI - PMC - PubMed
    1. Chen Y, Liu S, Wu L, Liu Y, Du J, Luo Z, et al. . Epigenetic regulation of chemokine (CC-motif) ligand 2 in inflammatory diseases. Cell Prolif (2023) 56(7):e13428. doi: 10.1111/cpr.13428 - DOI - PMC - PubMed
    1. Galipeau J. Macrophages at the nexus of mesenchymal stromal cell potency: The emerging role of chemokine cooperativity. Stem Cells (2021) 39(9):1145–54. doi: 10.1002/stem.3380 - DOI - PMC - PubMed

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
-